Pipeline

R&D PIPELINE

We established a diversified and comprehensive R&D pipeline covering oncology, autoimmune diseases, pain management, cardiovascular diseases, metabolic diseases, infectious diseases, respiratory system diseases, hematological diseases, neurological diseases, ophthalmology, etc.

Major R&D Pipelines

  • 27

    New Molecular Entity drugs marketed in China

  • 6

    Other innovative drugs marketed in China

  • 100

    +

    In-House Innovative Pharmaceuticals under Clinical Development

  • 400

    +

    Ongoing Clinical Studies       

  • 20

    +

    Ongoing International Clinical Studies

*By Jul,2026

Clinical Development Pipeline

Phase III
NDA/BLA
Oncology
Cardiovascular & Metabolism
Immunological & Respiratory
Neuro & Others

EGPA (eosinophilic granulomatosis with polyangiitis); HoFH (homozygous familial hypercholesterolemia); Nr-axSpA (non-radiographic axial spondyloarthritis); mCRPC (metastatic castration-resistant prostate cancer).
Notes: (1) US, Europe (2) US, Europe; (3) Europe; (4) US, Europe, Asia-Pacific (including China).

Phase II
Oncology
Cardiovascular & Metabolism
Immunological & Respiratory
Neuro & Others

Neo/adj (neoadjuvant/adjuvant), r/r (relapsed/refractory); mHNSCC (metastatic head and neck squamous cell carcinoma), NMIBC (non-muscle invasive bladder cancer), OC (ovarian cancer), HTG (hypertriglyceridemia), VTE (venous thromboembolism), IPF (Idiopathic pulmonary fibrosis).
Notes: (1) Combo with adebrelimab; (2) Combo with adebrelimab + SHR-8068; (3) US; (4) Mono / Combo; (5) US, Europe

Phase I
Oncology
Cardiovascular & Metabolism
Immunological & Respiratory
Neuro & Others
Notes: (1) US; (2) China, Australia; (3) China & US & Australia; (4) China & US & Australia; (5) Japan & Korea; (6) US; (7) Australia;(8) Europe; (9) US; (10) Australia; (11) Australia.